New System Will Play a Key Role in Delivering
Radiation Treatments in One of the Largest Cancer Facilities in
Washington State
MADISON,
Wis., Jan. 25, 2024 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that the Providence
Swedish Radiosurgery Center in Seattle,
Washington is enhancing its cancer treatment capabilities
with the purchase of the latest generation CyberKnife®
S7™ System, the hospital's second CyberKnife radiation delivery
device purchase. The precision and accuracy enabled by the system's
robotic design will also make it an ideal choice for the treatment
of neurologic disorders. The new system will enable the medical
team to deliver gold standard stereotactic radiosurgery (SRS) and
stereotactic body radiation therapy (SBRT) treatments faster than
with previous models, expanding access to an effective and
convenient option to more patients.
"The Providence Swedish Radiosurgery Center began using their
first CyberKnife System more than 10 years ago. Since then, we've
built a valuable partnership based on our mutual goal to transform
the cancer patient experience with technologies that improve
patient comfort during treatment and extend both survivorship and
quality of life post-treatment," said Suzanne Winter, President and CEO of Accuray. "I
couldn't be prouder that the Providence Swedish Radiosurgery team
is continuing to invest in Accuray technologies. It signifies their
confidence in our company, our people and our products."
The CyberKnife S7 System is a non-invasive radiation therapy
device that was built from the ground-up to provide clinicians with
the speed they need for operational efficiency without sacrificing
the precision and accuracy required for stereotactic radiosurgery
(SRS) and stereotactic body radiation therapy (SBRT). The system
uses artificial intelligence (AI) to track and automatically adapt
for tumor or patient movement during treatment, delivering the
radiation dose directly to the target with sub-millimeter precision
- in as little as 15 minutes.
"At Providence Swedish Radiosurgery Center, we recognize that
treatment decisions significantly impact patients' immediate health
and long term quality of life. Our top priority is to provide
excellent care for each person who walks through our door,
leveraging the latest innovations in radiation therapy technologies
and techniques to improve patient outcomes," said Dr. Christopher Loiselle, Executive Medical
Director, Providence Swedish Radiosurgery Center and President of
the Tumor Institute Radiation Oncology Group. "We have had a
successful experience with the CyberKnife System and a positive
relationship with the Accuray team. We purchased the CyberKnife S7
device because we are confident the system will further our ability
to meet our patient-centered treatment goals."
The Providence Swedish Radiosurgery Center team has made
significant contributions to the field of radiation medicine
including leading the first large, multi-center clinical trial with
long-term follow-up evaluating the use of SBRT in prostate cancer
delivered by the CyberKnife System. They also are actively involved
in research assessing the use of SBRT to treat tumors in other
areas of the body and radiosurgery in the treatment of cancer and
medical conditions in the brain.
Important Safety Information
For Important Safety Information please refer to
https://www.accuray.com/safety-statement.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions that are designed to deliver
radiation treatments for even the most complex cases—while making
commonly treatable cases even easier—to meet the full spectrum of
patient needs. We are dedicated to continuous innovation in
radiation therapy for oncology, neuro-radiosurgery, and beyond, as
we partner with clinicians and administrators, empowering them to
help patients get back to their lives, faster. Accuray is
headquartered in Madison,
Wisconsin, with facilities worldwide. To learn more, visit
www.accuray.com or follow us on Facebook, LinkedIn, X,
and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited to, expectations regarding the
company's goals and partnerships with customers; expectations
regarding future purchases by customers; the ability of the
company's products to meet the goals of its customers; patient
experiences and patient outcomes. If any of these risks or
uncertainties materialize, or if any of the company's assumptions
prove incorrect, actual results could differ materially from the
results expressed or implied by these forward-looking statements.
These risks and uncertainties include, but are not limited to, the
company's ability to achieve widespread market acceptance of its
products, including new product innovations and releases; the
company's ability to develop new products or improve existing
products to meet customers' needs; the company's ability to
anticipate or keep pace with changes in the marketplace; and the
direction of technological innovation and customer demands and such
other risks identified under the heading "Risk Factors" in the
company's Quarterly Report on Form 10-Q, filed with the Securities
and Exchange Commission (the "SEC") on November 7, 2023, and as updated periodically
with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contact:
Beth
Kaplan
Public Relations Director, Accuray
+1 (408)
789-4426
bkaplan@accuray.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/providence-swedish-radiosurgery-center-in-seattle-invests-in-second-accuray-cyberknife-system-a-robotic-delivery-device-that-makes-extremely-precise-radiation-treatments-possible-in-1-5-sessions-302044226.html
SOURCE Accuray Incorporated